SynthesisScientific reports2020
Metagenomic analysis of gut microbiota in non-treated plaque psoriasis patients stratified by disease severity: development of a new Psoriasis-Microbiome Index.
Synthesis in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
55 citing papers in PubMed, 3 syntheses or guidelines pooled it, 94 citations in OpenAlex.
- The Emerging Role of Gut Microbiota in Inflammatory Skin Diseases: A Systematic Review.Experimental dermatology · 2026Pooled it
- Characterization of the Gut Microbiota in Patients with Psoriasis: A Systematic Review.Pathogens (Basel, Switzerland) · 2025Pooled it
- Characterization of the Oral and Gut Microbiota in Patients with Psoriatic Diseases: A Systematic Review.Acta dermato-venereologica · 2021Pooled it
- Transforming Psoriasis Care: Probiotics and Prebiotics as Novel Therapeutic Approaches.International journal of molecular sciences · 2023Trial
- Trial
- Review
- Obesity, skin disorders, and the microbiota: Unraveling a complex web.Journal of microbiology (Seoul, Korea) · 2026Review
- Gut Microbiota in Psoriasis: Evidence for Dysbiosis, Pathological Mechanisms, Causality, and Therapeutic Implications.Clinical, cosmetic and investigational dermatology · 2026Review
- Psoriasis: microbiome dysbiosis and pathogenic mechanisms.Frontiers in immunology · 2026Review
- Gut microbiota constituents may affect hypertrophic scarring risk through interaction with specific immune cells in a two-step, two-sample Mendelian randomization study.Scientific reports · 2025Article
- Skin microbiome and dermatologic disorders.The Journal of clinical investigation · 2025Review
- Review
- The impact of IL-17A inhibitors on scalp and gut microbiota in psoriasis.Frontiers in cellular and infection microbiology · 2025Article
- Article
- Healthy human gut microbiome: Towards standardized research.AIMS microbiology · 2025Review
- Fecal microbiota transplantation for the treatment of chronic inflammatory skin diseases.Heliyon · 2024Review
- Study of gut microbiome alterations in plaque psoriasis patients compared to healthy individuals.Postepy dermatologii i alergologii · 2024Article
- No Evidence of Gut Microbiota Alteration in Psoriasis Patients Switching to Brodalumab after Loss of TNFα Inhibition Effect.International journal of molecular sciences · 2024Article
- Correlations between Gut Microbiota and Hematological, Inflammatory, Biochemical and Oxidative Stress Parameters in Treatment-Naïve Psoriasis Patients.International journal of molecular sciences · 2024Observational
- TLR7-dependent eosinophil degranulation links psoriatic skin inflammation to small intestinal inflammatory changes in mice.Experimental & molecular medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Psoriasis is an immune-mediated skin disorder. Imbalance of gut microbial populations has been implicated in many diseases. We aimed to investigate whether there were differences in gut microbiota in psoriasis patients vs non-psoriasis controls and between psoriasis severity groups. 55 psoriasis patients and 27 controls were included. V3-V4 regions of the 16S rRNA gene of fecal samples were analyzed using Illumina MiSeq. Bioinformatic analysis was performed. We found changes in gut microbiome composition depending on their psoriasis status as determined by weighted unifrac (p < 0.05), in particular an increase in Firmicutes and depletion of Bacteroidetes in psoriasis patients. Additionally, the Faecalibacterium and Blautia genus were higher in psoriasis patients while Bacteroides and Paraprevotella in non-psoriasis controls (p < 0.05, LDA score > 2). Moderate-to-severe psoriasis patients had lower biodiversity than mild psoriatic patients (p = 0.049). No differences for beta-diversity were found. We developed a Psoriasis-Microbiota Index (PMI), which discriminated among psoriasis patients and controls with sensitivity: 0.78 and specificity: 0.79. Furthermore, we performed a meta-analysis with published data to validate this index. We demonstrated gut dysbiosis in psoriasis patients, suggesting a role in psoriasis pathophysiology. Furthermore, we developed a PMI with the potential to discriminate between psoriasis patients and controls across different populations, which could be used as a biomarker in the clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.